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More pumps—more questions
To the Editor:
We would like to congratulate Wilhelm
and colleagues1 on their outstanding results
concerning long-term survival after the im-
plantation of axial flow left ventricular as-
sist devices (LVADs). Since the worldwide
first implantation of the axial flow pump in
our institution on November 13, 1998,2 fol-
lowed by implantations in Vienna 1 week
later,3 these pumps have increasingly
gained acceptance. Long-term LVAD sup-
port not only enables patients to be bridged
to heart transplantation or recovery but also
opens up the opportunity to prolong high-
quality life for nontransplant candidates.
The article presented also shows that long-
term nonpulsatile or less-pulsatile blood
flow is not detrimental for the function of
the end organs. Our experience with 44
patients who were supported with rotary
blood pumps for more than 200 days ac-
cords with the results presented by the au-
thors. However, good long-term results can
also be achieved with pulsatile systems. Of
a total of 110 patients supported with an
LVAD for longer than 200 days in our
institution, 66 had pulsatile devices. Of
these, 3 patients were supported for more
than 4 years with the Novacor LVAS and 2
with the BerlinHeart Excor.4
During long-term support, appropriate
anticoagulation plays a key role for the
survival and complication rates. As antico-
agulative medication with the rotary
pumps, we now administer phenprocou-
mon with a target international normalized
ratio of 2.5, aspirin, and, in patients sup-
ported with axial flow pumps, additional
clopidogrel according to platelet aggrega-
tion tests, taking polymorphism of the
platelet GP IIb/IIIa receptors into consid-
eration.5 In our opinion the aspirin dose
should not exceed 100 mg/d.
We would be interested in the authors’
current anticoagulation protocols and whether
they used different regimens in patients
with different rotary blood pumps. Second,
based on the experience gained in Münster,
are there any preferences of pump type for
destination therapy?
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Reply to the Editor:
Left ventricular assist device (LVAD) sup-
port was originally used to bridge high risk
patients to heart transplantation.1 After in-
creased experience with this therapy
showed that the failing native heart may
have the potential to recover, LVAD ther-
apy provided the option of weaning se-
lected patients from mechanical support as
an alternative to transplantation.2 As tech-
nology made further progress, the duration
of support has increased markedly and
paved the way for destination therapy.
Device selection, however, in particular
for long-term support, still remains an un-
resolved question. Most centers have expe-
rience with one or two types of devices.
Devices are selected on the basis of per-
sonal experience. As long as people are
satisfied with the devices they are using,
they do not see a reason to change to other
systems. Only centers that handle large
numbers of patients use a variety of de-
vices, which offers them the opportunity to
compare systems. Prospective randomized
studies to evaluate different devices for
different indications have not yet been
performed.
It is of foremost importance that
LVADs meet the criteria of long-term reli-
ability and excellent quality of life in ad-
dition to the standard requirements of low
frequency of infection and thromboembo-
lism. The intracorporeal pulsatile devices
such as the Novacor LVAS and the Heart-
Mate I have demonstrated reliability for
long-term support.3,4 Extracorporeal pulsa-
tile devices such as the Thoratec LVAD
and the Berlin Heart Excor also have sup-
ported patients over the long term.5,6 The
introduction of axial-flow pumps revolu-
tionized mechanical circulatory support.
Pump size was markedly reduced, which
facilitated the implantation procedure.
Bleeding and infectious complications be-
came less frequent. Because axial-flow
pumps have not been on the market as long
as pulsatile devices, their long-term reli-
ability still has to be proved. Some patients
were supported for more than 1 year with
the DeBakey VAD, the Jarvik 2000, or the
Berlin Heart Incor, respectively.7-9 In par-
ticular, the Berlin Heart Incor promises
good long-term performance because of the
magnetic suspension of its impeller, which
provides virtually unlimited durability. The
longest support period with this device is
about 3 years. The design of axial-flow
pumps renders the exchange of single parts
less invasive than is required for larger
pulsatile devices.
Axial-flow pumps appear to provide a
better quality of life than pulsatile devices.
They are much smaller than intracorporeal
pulsatile pumps, which makes them easier
to implant in the pericardium. There is no
need for placement in the abdominal wall
or in the abdomen, which may cause gas-
trointestinal and digestive complications.
In addition, the axial-flow pumps run si-
lently, whereas the clatter of pulsatile de-
vices accompanies the patient and his en-
vironment day and night. Extracorporeal
pulsatile systems are associated with an
additional aesthetic and psychological dis-
advantage. The pump chambers, which are
located permanently outside the body, re-
Letters to the Editor
210 The Journal of Thoracic and Cardiovascular Surgery ● July 2006
